Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

How may anticancer chemotherapy with fluorouracil be individualised?

Clinical pharmacokinetics - 1 Jan 2006

Ploylearmsaeng Su-arpa, Fuhr Uwe, Jetter Alexander

Abstract excerpt

Fluorouracil is used clinically against various solid tumours. Both fluorouracil toxicity and pharmacokinetics vary highly within and between individuals. The reasons why doses are not individualised routinely are difficulties in defining, predicting and achieving an optimal fluorouracil exposure or dose because of a narrow therapeutic index, nonlinear pharmacokinetics, variabilities in administration rates and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antimetabolites, Antineoplastic
Share to Clinical Trials as Topic
Share to Dihydrouracil Dehydrogenase (NADP)

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Fluorouracil

Share to Genotype

Share to Neoplasms

Share to Pharmacogenetics

Share to Phenotype

Source

Identifiers

PMID: 16719540
DOI: 10.2165/00003088-200645060-00002

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

How may anticancer chemotherapy with fluorouracil be individualised?PMID 16719540Read ↗

Individualized Dosing of Fluoropyrimidine-Based Chemotherapy to Prevent Severe Fluoropyrimidine-Related Toxicity: What Are the Options?Semantic proximity Read ↗

Phenotype versus genotype to optimize cancer dosing in the clinical setting-focus on 5-fluorouracil and tyrosine kinase inhibitors.Semantic proximity Read ↗

Pharmacogenetics in cancer chemotherapy: balancing toxicity and response.Semantic proximity Read ↗

DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysisSemantic proximity Read ↗

Toward individualized treatment: prediction of anticancer drug disposition and toxicity with pharmacogeneticsSemantic proximity Read ↗

Pharmacokinetic optimisation of cancer chemotherapy. Effect on outcomes.Semantic proximity Read ↗

Biochemical and clinical pharmacology of 5-fluorouracil.Semantic proximity Read ↗

The Role of Pharmacogenetics and Pharmacogenomics in Cancer Chemotherapy with 5-FluorouracilSemantic proximity Read ↗

DPYD genotype-guided dose individualization to improve patient safety of fluoropyrimidine therapy: call for a drug label updateSemantic proximity Read ↗

Dihydropyrimidine dehydrogenase phenotype-guided dose individualization of fluoropyrimidine in gastrointestinal cancers: PRODIGE100-UCGI48-FUDOSE phase II study.Semantic proximity Read ↗

Pharmacogenetics: a tool for individualizing antineoplastic therapy.Semantic proximity Read ↗

Genotypes Affecting the Pharmacokinetics of Anticancer Drugs.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.